Pulmonary Complications of Lung Cancer Treatment

Lynn Tanoue, MD
Professor of Medicine
Yale University School of Medicine
New Haven, CT, USA
Outline

- Approach to the patient with suspected treatment-related pulmonary toxicity
- Pulmonary toxicity related to tyrosine kinase inhibitors
- Pulmonary toxicity related to immunotherapy
Pulmonary Toxicities related to Cancer Treatment

- 10% of all cancer patients develop pulmonary toxicity related to treatment
- Patients with lung cancer appear to be at increased risk for pulmonary complications of treatment
  - High prevalence of underlying lung disease (COPD, ILD, etc.)
    - Decreased baseline pulmonary reserve
  - Diagnosis of toxicity may be difficult or delayed
    - Symptoms of toxicity may mimic symptoms of known disease
    - Radiographic findings not specific
    - Risk of pulmonary infection in immunosuppressed patients is high
  - Threshold for diagnostic evaluation, including invasive procedures, should be low
Approach to the patient with suspected treatment-related pulmonary toxicity

Typical symptoms are nonspecific
• Progressive dyspnea, nonproductive cough, chest discomfort, weight loss

In most cases, the diagnosis of drug toxicity is one of exclusion
• Exclude progression of underlying cancer
• Exclude other competing causes of pulmonary decompensation
  o Infection, congestive heart failure, noncardiogenic pulmonary edema
• Consequences of concluding drug toxicity are clinically important
  o Will influence decision regarding continuation of therapy
Approach to the patient with suspected pulmonary toxicity

Evaluation

• Assess risk for infection
  o Neutropenia, immunosuppression
  o Lungs are the most common site of infection in cancer patients
• Pulmonary function testing with diffusion capacity (compare to baseline)
• Imaging studies: CXR, Chest CT (inspiration/expiration high resolution), echocardiogram, etc.
  o Is there evidence for a competing diagnosis (pleural/pericardial effusion, pulmonary edema, adenopathy, evidence of disease progression, etc.)
• Bronchoscopy with BAL and TBBx (role for cryobiopsy?)
• Transthoracic, CT-guided biopsy
• Surgical lung biopsy
### Pulmonary Toxicities related to Cancer Treatment

<table>
<thead>
<tr>
<th>Class of Drug</th>
<th>Pulmonary toxicities</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Platinum drugs</td>
<td>Pneumonitis (rare), Hypersensitivity reactions (rare)</td>
<td>Withdraw drug. For severe toxicity (symptomatic, radiographic, physiologic findings), consider corticosteroids</td>
</tr>
<tr>
<td>Pemetrexed</td>
<td>Pneumonitis (rare)</td>
<td></td>
</tr>
<tr>
<td>Etoposide</td>
<td>Pneumonitis (rare), Hypersensitivity reactions (rare)</td>
<td></td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>Nonspecific dyspnea (25%), pneumonitis (rare), diffuse alveolar damage (rare), risk factors: age, prior radiation</td>
<td></td>
</tr>
<tr>
<td>Taxanes</td>
<td>Higher risk associated with ILD. Type 1 hypersensitivity reactions, pneumonitis. Increase risk of radiation injury (radiation recall)</td>
<td></td>
</tr>
<tr>
<td>Camptothecins</td>
<td>Pneumonitis, higher risk with ILD or prior radiation.</td>
<td></td>
</tr>
<tr>
<td>Anti-angiogenic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Hemoptysis (higher in patients with squamous cell carcinoma or cavitary tumors), diffuse alveolar hemorrhage, T-E fistula with concurrent chemoradiation (? Increased VTE)</td>
<td>Withdraw drug. Symptomatic support.</td>
</tr>
</tbody>
</table>

#### Class of Drug:
- **Chemotherapy**
- **Anti-angiogenic agents**

#### Pulmonary Toxicities:
- **Chemotherapy**
  - Platinum drugs: Pneumonitis (rare), Hypersensitivity reactions (rare)
  - Pemetrexed: Pneumonitis (rare)
  - Etoposide: Pneumonitis (rare), Hypersensitivity reactions (rare)
  - Gemcitabine: Nonspecific dyspnea (25%), pneumonitis (rare), diffuse alveolar damage (rare), risk factors: age, prior radiation
  - Taxanes: Higher risk associated with ILD. Type 1 hypersensitivity reactions, pneumonitis. Increase risk of radiation injury (radiation recall)
  - Camptothecins: Pneumonitis, higher risk with ILD or prior radiation

#### Approach:
- Withdraw drug. For severe toxicity (symptomatic, radiographic, physiologic findings), consider corticosteroids
- Withdraw drug.
- Symptomatic support.
The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.
Dijon, France

Search results:

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Patterns</th>
<th>Publications</th>
<th>Medias</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOLFIRI chemotherapy regimen</td>
<td>2</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>0</td>
<td>7</td>
<td>0</td>
</tr>
</tbody>
</table>

1 - Interstitial/parenchymal lung disease
1.b - Pneumonitis (ILD)
The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.
Dijon, France

Irinotecan

Pneumonitis (ILD)

Last update: 10/07/2012

SEARCH

Search by keyword

Diagnosing DIRD

PUBLICATIONS

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.

Anti-cancer drugs 2011 Jul;22,663-8 2011 Jul

Irinotecan-induced interstitial pneumonia.
The Lancet. Oncology 2004 May;5:322-4 2004 May

Irinotecan-associated pulmonary toxicity.
Genotype-directed targeted therapies

• Potentially targetable mutations are identified for the majority of adenocarcinomas
• Targeted tyrosine kinase inhibitors are first line therapies for patients with advanced (Stage IV) EGFR-mutated, ROS1 and ALK rearranged NSCLC
  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI)
    • gefitinib, erlotinib, afatinib (EGFR/HER2), osimertinib
  • ROS1 TKI
    • crizotinib
  • Anaplastic lymphoma kinase (ALK) rearrangement TKI
    • crizotinib, ceritinib, alectinib
Pulmonary toxicity related to tyrosine kinase inhibitors

- All tyrosine kinase inhibitors can cause pulmonary toxicity
- EGFR inhibitors (gefitinib, erlotinib, afatinib, osimertinib)
  - 7-8% of patients develop treatment-limiting toxicities (skin, GI, lungs)
  - Most common toxicity is pulmonary: interstitial pneumonitis
    - Risk factors: Asian descent (6%), pre-existing ILD, older age, male gender, smoking, prior thoracic irradiation
    - Typically occurs quickly, within first 2 months of treatment, but may appear after many months
    - Symptoms: dry cough, exertional dyspnea
    - Treatment: discontinue drug, initiate corticosteroids for radiographic findings in combination with symptoms
    - Fatal pneumonitis observed in 2% of Japanese patients, but rare in other populations
- NB: TKIs are not immunosuppressing, and do not increase risk of infection
Case 1
RD is a 71 year old female, who presented in December 2017 with complaints of persistent dry cough and back pain for 4 months and recent 10 pound weight loss. She is a lifelong nonsmoker and had previously been in good health. A chest radiograph suggested a left lung mass; chest CT scan confirmed a 4 cm spiculated mass in the left lower lobe with mediastinal adenopathy. PET-CT imaging showed intense FDG uptake in the mass, mediastinal nodes, supraclavicular nodes, and several liver lesions. Brain MRI was negative.

Aspiration of a one of the liver lesions demonstrated TTF+ adenocarcinoma, + EGFR Exon 19-deletion mutation. Tumor PD-L1 expression was < 1%. The clinical stage was T2aN3M1c, Stage IVc.
Case 1: 71 year old women with *EGFR*-mutated adenocarcinoma (Exon 19-deletion mutation). Clinical stage: T2aN3M1c, Stage IVc.

Which of the following would NOT be an appropriate recommendation?

A. Gefitinib  
B. Erlotinib  
C. Crizotinib  
D. Osimertinib
Case 1: 71 year old women with EGFR-mutated adenocarcinoma (Exon 19-deletion mutation). Clinical stage: T2aN3M1c, Stage IVc.

Which of the following would NOT be an appropriate recommendation?

A. Gefitinib  
B. Erlotinib  
C. Crizotinib  
D. Osimertinib
Case 1

• RD was treated with erlotinib. Over the first 3 months, the cough and back pain resolved, and there was marked improvement in her radiographs. In July of 2018, she developed persistent dry cough without other symptoms. Chest CT scan demonstrated that the original primary mass had decreased in size to 1.7 cm and mediastinal adenopathy had resolved, but the lung parenchyma demonstrated diffuse interstitial and ground glass infiltrates in all lung zones. Pulmonary function testing showed a mild restrictive defect with a decrease in diffusion capacity, both new compared to pre-treatment testing.
Case 1: Which of the following is the most likely explanation for the radiographic findings in June 2018?

A. Pneumocystis jiroveci pneumonia  
B. Diffuse alveolar hemorrhage  
C. Interstitial pneumonitis due to erlotinib  
D. Lymphangitic spread of adenocarcinoma
Question 2

Case 1: Which of the following is the most likely explanation for the radiographic findings in June 2018?

A. Pneumocystis jiroveci pneumonia
B. Diffuse alveolar hemorrhage
C. Interstitial pneumonitis
D. Lymphangitic spread of adenocarcinoma
Case 1

- Bronchoscopy with BAL and biopsies of the right lung showed no evidence of infection or cancer.
- RD was felt to have erlotinib-related pulmonary toxicity with acute interstitial pneumonitis. Erlotinib was discontinued and she was treated with oral corticosteroids for 3 months, with improved symptoms and PFT.

June 2018
Case 1

- In October 2018, a surveillance CT showed the diffuse interstitial infiltrates had improved. However, the primary site had increased to 2.1 cm.
- Carboplatin and pemetrexed were begun x 4 cycles. RD tolerated the chemotherapy well, but in January 2019, brain MRI showed two new 6 mm enhancing nodules in the right parietal lobe, consistent with metastasis. She received gamma knife treatment to the brain metastasis.
Case 1

- With evidence of recurrent disease despite chemotherapy, a tumor board multidisciplinary discussion was held.
- Because RD had $EGFR$-mutant adenocarcinoma, it was felt that immunotherapy was unlikely to be of benefit.
- It was noted that RD had never had treatment failure with erlotinib – the drug had been discontinued because of toxicity, not because of development of resistance.
- The recommendation of the tumor board was to consider osimertinib, but with careful monitoring given the prior pulmonary toxicity with erlotinib.
Case 1

- An informed discussion was held with RD to explain the tumor board recommendations. Osimertinib was started in late January 2019.
- Within 6 weeks, RD began experiencing dry cough without fevers.
- Chest CT demonstrated diffuse interstitial infiltrates with areas of atelectasis and consolidation, felt most likely consistent with drug toxicity from osimertinib.
- Osimertinib was discontinued. RD is currently being treated with oral corticosteroids, with improvement in dyspnea.
Take home points: Pulmonary toxicity related to tyrosine kinase inhibitors

• All tyrosine kinase inhibitors can cause pulmonary toxicity
• Symptoms of pulmonary toxicity are nonspecific (dry cough, dyspnea) and may mimic the patient’s underlying cancer or other lung disease, so suspicion always needs to be high
• Drug toxicity usually manifests radiographically as interstitial pneumonitis
• Drug toxicity usually occurs within the first few months of treatment, but can appear late, after many months
• TKIs are not immunosuppressing. Concern for pulmonary infection in a patient with lung cancer must be present, but the risk is not as high as with chemotherapy
• Treatment: discontinue drug, initiate corticosteroids for radiographic findings in combination with symptoms
Immunotherapy for treatment of lung cancer

- Checkpoint inhibitors approved for treatment of Stage IV NSCLC
  - Anti PD-1
    - Pembrolizumab (for high PD-L1 expressing tumors)
    - Nivolumab
  - Anti PD-L1
    - Durvalumab
    - Atezolizumab
    - Avelumab
  - Anti-CTLA4
    - Ipilimumab
    - Tremelimimumab
Immune-related adverse events (IRAEs) - NSCLC


23 studies of immunotherapy for NSCLC, including 5744 patients with complete data on IRAEs
Immune-related adverse events (IRAEs) related to checkpoint inhibitors - NSCLC

Risk factors:
• Underlying interstitial lung disease
• Underlying auto-immune disease (typically a disqualification to eligibility for clinical trials with checkpoint inhibitors)
• Prior thoracic irradiation
Immune-related adverse events (IRAEs) – time frame


Figure 2
Median time to onset immune-related adverse events for different toxicities with anti-PD-1 (nivolumab) in NSCLC patients. Circles represent medians; bars signify ranges. Inf. reaction, infusion reaction or hypersensitivity; NSCLC, non-small cell lung cancer.
Case 2

FD is a 52 year old man, diagnosed with Stage IV NSCLC in 2014 (primary site in right upper lobe, extensive mediastinal adenopathy, single metastatic focus in the right adrenal gland). The tumor was an adenocarcinoma, *EGFR* mutation-negative, ALK-rearrangement-negative, tumor PD-L1 expression > 50%. He was entered into a clinical trial comparing chemotherapy to pembrolizumab in late 2014.
Case 2

- 6 cycles into treatment, he had resolution of the adrenal metastasis and mediastinal adenopathy, and a decrease in size of the primary tumor. However, after the 8th cycle, he presented with new onset cough and exertional dyspnea, and oxygen desaturation with ambulation. He had no fever, chest discomfort or other symptoms.
- CT demonstrated that the RUL lesion had not changed, but he had new infiltrates in the right upper and lower lobes.
- Concern was raised about the possibility of pembrolizumab-associated pulmonary toxicity
Approach to the evaluation and management of suspected immunotherapy-related pulmonary toxicity

1. Assess severity of initial clinical/radiographic presentation
   • Grade 1: Asymptomatic with radiographic changes
   • Grade 2: Symptomatic but no limitation of usual activity
   • Grade 3: Symptomatic, with oxygen requirement or limitation of activity
   • Grade 4: Severe or life-threatening

2. Exclude alternative diagnoses
   • Exclude pulmonary infection
   • Exclude other pulmonary complications (PE, hemorrhage, etc.)
Approach to the evaluation and management of suspected immunotherapy-related pulmonary toxicity

3. Approach initial management based on grade of toxicity
   • Grade 1: Continue therapy with close observation, escalate to treatment for symptoms or radiographic worsening
   • Grade 2: Hold therapy, consider bronchoscopy, institute oral prednisone 1 mg/kg/day if no improvement
   • Grade 3-4: Discontinue therapy, bronchoscopy, institute oral prednisone 1-2 mg/kg/day or IV corticosteroids at equivalent dose

4. Assess response to management
   • Taper steroids over 4-6 weeks as directed by response
   • For mild cases, can consider rechallenge with immunotherapy
   • If no response, consider surgical lung biopsy to clarify process
Case 2

- FD declined bronchoscopy. CT-guided core needle biopsy revealed organizing pneumonia. Cultures from the biopsy were negative.
- Contrast CT – negative for pulmonary embolism, no evidence for mediastinal adenopathy
- Assessment: Pembrolizumab-associated organizing pneumonia, Grade 3 IRAE

November 2016
Case 2

- FD was started on prednisone at 1 mg/kg/day in late 2016
- By February 2017, the right upper lobe infiltrate had substantially improved and the right lower lobe infiltrate had resolved. Prednisone was tapered off.
- FD has not received any further cancer therapy. He remains clinically without evidence of recurrence of cancer.
Case 3  
(courtesy Scott Gettinger MD and Jennifer Possick MD, Yale Thoracic Oncology Program)

- A 60 year old woman, 30 pack-year former smoker, has a history of LLLobectomy and adjuvant vinorelbine and docetaxel in 2010 for T2aN1M0 adenocarcinoma.

- She was disease-free until 2014, when she was noted to have a growing 8 mm RLL nodule. This was felt clinically to be a second primary; the patient underwent RLL wedge resection that confirmed adenocarcinoma.

- In 2015 she developed several more small, bilateral pulmonary nodules. CT-guided needle biopsy of a right middle lobe 6 mm nodule again demonstrated adenocarcinoma. At this time it was felt she had Stage IV disease with multiple pulmonary metastases. She was treated with a platinum based chemotherapy doublet, which she tolerated poorly. Follow up chest CT demonstrated that the nodules were again increasing in size and were more numerous.
Case 3

The patient’s performance status is 0-1. Molecular testing of the most recently resected adenocarcinoma shows no targetable mutations. Which of the following would you recommend for treatment?

A. Pemetrexed
B. Erlotinib
C. Immune checkpoint inhibitor
D. SBRT to the largest nodules
Case 3

The patient’s performance status is 0-1. Molecular testing of the most recently resected adenocarcinoma shows no targetable mutations. Which of the following would you recommend for treatment?

A. Pemetrexed  
B. Erlotinib  
C. Immune checkpoint inhibitor  
D. SBRT to the largest nodules
The patient was started on Nivolumab on an every 3 week schedule. 6 weeks into treatment, chest CT demonstrated that the nodules were increasing in size, and some demonstrated adjacent ground glass infiltrate.
3 months into treatment, the patient was generally feeling well, with a mild non-productive cough and occasional low grade fever.
Case 3

What do you feel is the most likely explanation for this patient’s radiographic progression?

A. Progression of malignancy
B. Infectious process
C. Pseudo-progression related to Nivolumab
D. Hypersensitivity reaction to Nivolumab
Question 4

Case 3

What do you feel is the most likely explanation for this patient’s radiographic progression?

A. Progression of malignancy
B. Infectious process
C. Pseudo-progression related to Nivolumab
D. Hypersensitivity reaction to Nivolumab
Question 5

Case 2

What would you recommend to this patient as the next step?

A. Bronchoscopy
B. Surgical lung biopsy
C. Prednisone 60 mg/day and continue Nivolumab
D. Discontinue Nivolumab
Question 5

Case 2

What would you recommend to this patient as the next step?

A. Bronchoscopy
B. Surgical lung biopsy
C. Prednisone 60 mg/day and continue Nivolumab
D. Discontinue Nivolumab
• Bronchoscopy was performed, with BAL and transbronchial biopsies
• Culture of BAL was negative
• Transbronchial biopsies:
  • No malignant cells
  • Lymphocytic infiltrate with foamy macrophages
  • No granuloma, eosinophils, organizing pneumonia, or type II pneumocyte hyperplasia
The patient had no further treatment. Nivolumab was discontinued. She remained without evidence of active disease 1 year after Nivolumab was discontinued.
Take home points – Pulmonary toxicity related to Immunotherapy

- Approximately 4% of patients with NSCLC treated with immunotherapy develop pulmonary toxicity in the setting of clinical trials
  - This may under-estimate the number of patients with NSCLC treated with immunotherapy who develop pulmonary toxicity in general practice
  - Anti-PD1 agents have an increased likelihood of toxicity, compared to anti-PDL1 agents
- Assessment of the grade of toxicity is important, and will guide treatment
  - Radiographic changes may reflect treatment response, not toxicity. The determination of response vs. toxicity will inform decision making
- Treatment of IRAEs with corticosteroids does not appear to affect treatment response
Pulmonary Complications of Lung Cancer Treatment

- 10% of all cancer patients develop pulmonary toxicity related to treatment
- Patients with lung cancer appear to be at increased risk for pulmonary complications of treatment
- Resource for drug toxicities: Pneumotox.com
- Targeted therapy tyrosine kinase inhibitors
  - 7-8% of patients develop treatment-limiting toxicities (skin, GI, lungs)
  - Risk factors: Asian descent (6%), pre-existing ILD, older age, male gender, smoking, prior thoracic irradiation
- Immunotherapy
  - 4% of patients develop treatment-related pulmonary toxicity
- Threshold for diagnostic evaluation, including invasive procedures, should be low